MUMBAI, March 31 (Reuters) - Indian biotechnology firm Biocon Ltd could file a prospectus for a share listing for its research services business arm Syngene International (IPO-SYNN.NS) within the next two months, two sources directly involved in the process said.
The IPO could fetch up to 10 billion rupees ($159.8 million), said one of the sources. However, the sources did not specify how much was being sold in Syngene. Biocon had said in January it was looking to sell up to 15 percent of its stake via an IPO.
10:27 India's Tata Consultancy third-quarter net up 10.9 percent, beats estimates20
16:50 Goldman Sachs, Citigroup earnings confirm Trump effect on banks16
13:48 Wells Fargo Profit Falls 5.4% as Mortgage Revenue Declines24
13:21 Bank of America profits surge on cost cuts, trading gains25